TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27614630

Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection (FMD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Quadrant scaling (QS)
Number of subjects: 30
Study: 25723580

Group type: EXPERIMENTAL
Intervention: Short-stemmed prosthesis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional hip replacement
Number of subjects: 100
Study: 24090993

Group type: EXPERIMENTAL
Intervention: Deep massage therapy to posterior calf muscles and neural mobilization with self-stretch exercise program (DMS)
Number of subjects: 69
Study: 23045537

Group type: EXPERIMENTAL
Intervention: Patient navigation
Number of subjects: 993

Group type: COMPARATOR
Intervention: No navigation (control)
Number of subjects: 993
Study: 19216776

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Truview laryngoscope
Number of subjects: 21

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 21
Study: 17241150

Group type: EXPERIMENTAL
Intervention: Midodrine (sympathomimetic)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15042502

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask (PS-LMA)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Endotracheal intubation (ET)
Number of subjects: 104
Study: 11777715

Group type: EXPERIMENTAL
Intervention: Heparin sodium (10 IU/mL) in irrigation solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard irrigating solution without heparin sodium
Number of subjects: 50
Study: 11739983

Group type: EXPERIMENTAL
Intervention: Aspirin users (509 patients)
Number of subjects: 1275

Group type: COMPARATOR
Intervention: Nonusers (766 patients)
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Aspirin users and Nonusers
Number of subjects: 1275
Study: 9406835

Group type: EXPERIMENTAL
Intervention: Alpha-blocker (terazosin) 2 mg/d for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo tablet for 6 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alpha-blocker (terazosin)
Number of subjects: 30
Study: 8500302

Group type: EXPERIMENTAL
Intervention: Oral prednisone or intravenous methylprednisolone followed by oral prednisone
Number of subjects: 457

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 457
Study: 3553200

Group type: EXPERIMENTAL
Intervention: Ceftazidime (14 patients)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Aminoglycoside (13 patients)
Number of subjects: 27
Study: 29705468

Group type: EXPERIMENTAL
Intervention: TENS plus therapeutic ultrasound
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control CNP group (discouraged from using analgesics, allowed paracetamol)
Number of subjects: 64
Study: 27717552

Group type: EXPERIMENTAL
Intervention: NPC‐01 (0.02 mg ethinyl estradiol and 1 mg norethisterone)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: IKH‐01 (0.035 mg ethinyl estradiol and 1 mg norethisterone)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: NPC‐01
Number of subjects: 215
Study: 25325894

Group type: EXPERIMENTAL
Intervention: High aspiration flow rate (40 cc/min; bottle height: 110 cm; vacuum: 400 mm Hg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low aspiration flow rate (20 cc/min; bottle height: 90 cm; vacuum: 400 mm Hg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High aspiration flow rate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low aspiration flow rate
Number of subjects: 80
Study: 20815129

Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy Program (dietary strategies)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Questionnaire measuring adherence (0-100%)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Self-perception of adherence (0-100%)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Glycemic control (capillary glucose self-monitoring)
Number of subjects: 69
Study: 18268073

Group type: EXPERIMENTAL
Intervention: Thrice-daily BIAsp 30
Number of subjects: 321

Group type: COMPARATOR
Intervention: Twice-daily BIAsp 30
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 321
Study: 15741434

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (800 microg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 14506118

Group type: EXPERIMENTAL
Intervention: Prolonged antithrombotic pretreatment (3 to 5 days)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Early intervention (less than 6 hours after pretreatment)
Number of subjects: 410
Study: 10382879

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (200 mg or 400 mg/day for 7 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lomefloxacin (400 mg/day for 7 days)
Number of subjects: 32
Study: 9279672

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1%
Number of subjects: 51

Group type: COMPARATOR
Intervention: Flurbiprofen 0.03%
Number of subjects: 51
Study: 1948834

Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen therapy (Estraderm)
Number of subjects: 22
Study: 29040773

Group type: EXPERIMENTAL
Intervention: Microsurgery
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Gamma Knife Radiosurgery (GKS)
Number of subjects: 105
Study: 27215836

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 43

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 43
Study: 25159343

Group type: COMPARATOR
Intervention: Didactic slide‐based lectures (SBL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fresh tissue cadaver‐based training (CBT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both SBL and CBT
Number of subjects: 40
Study: 22718840

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 107
Study: 20457948

Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 18368950

Group type: EXPERIMENTAL
Intervention: Test formulation of cefadroxil (500 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of cefadroxil (500 mg)
Number of subjects: 24
Study: 16572062

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (given twice daily during antibiotic therapy)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 12658070

Group type: EXPERIMENTAL
Intervention: Naloxone (0.15 mg/70 kg, i.m.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone in combination with Clonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Drug B)
Number of subjects: 0
Study: 10893848

Group type: EXPERIMENTAL
Intervention: Risk group with baseline FG/I ratio and IL 2-h PG within the lower and upper quartile, respectively.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group with baseline FG/I ratio and IL 2-h PG within the second and third quartiles, respectively.
Number of subjects: 96
Study: 9108813

Group type: EXPERIMENTAL
Intervention: Paroxetine 20-40 mg/day
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Clomipramine 75-150 mg/day
Number of subjects: 1002
Study: 8475955

Group type: EXPERIMENTAL
Intervention: 60 mg of aspirin from randomization to delivery
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo treatment from randomization to delivery
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 60 mg of aspirin
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 600
Study: 2435661

Group type: EXPERIMENTAL
Intervention: biofiltration‐PAN system
Number of subjects: 12

Group type: COMPARATOR
Intervention: acetate-cuprophan hemodialysis
Number of subjects: 12
Study: 31433347

Group type: EXPERIMENTAL
Intervention: KET/DEX (0.3 mg/kg bolus followed by 0.15 mg/kg/h infusion of ketamine + 0.7 μg/kg/h infusion of dexmedetomidine for 1.5 hours)
Number of subjects: 39

Group type: COMPARATOR
Intervention: KET/FENT (0.3 mg/kg bolus followed by 0.15 mg/kg/h infusion of ketamine + three 25 μg fentanyl injections for 1.5 hours)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: KET/DEX
Number of subjects: 39
Study: 30179953

Group type: EXPERIMENTAL
Intervention: Dexamethasone and lidocaine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Lidocaine alone (placebo)
Number of subjects: 106
Study: 27177588

Group type: EXPERIMENTAL
Intervention: Evidence-based cardiovascular risk management (CVRM)
Number of subjects: 1671

Group type: EXPERIMENTAL
Intervention: Training practice status
Number of subjects: 1671

Group type: COMPARATOR
Intervention: Nurse involvement in CVRM tasks
Number of subjects: 1671

Group type: COMPARATOR
Intervention: Practice size
Number of subjects: 1671
Study: 25193529

Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy (none, mild nonproliferative, moderate/severe)
Number of subjects: 1862
Study: 21993914

Group type: EXPERIMENTAL
Intervention: Radiofrequency kyphoplasty (RFK)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Balloon kyphoplasty (BKP)
Number of subjects: 114
Study: 19861358

Group type: EXPERIMENTAL
Intervention: Hemisync sounds
Number of subjects: 60

Group type: COMPARATOR
Intervention: Music
Number of subjects: 60

Group type: COMPARATOR
Intervention: Blank cassette tape (control)
Number of subjects: 60
Study: 18277064

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15711829

Group type: EXPERIMENTAL
Intervention: Cytokine treatment (Interleukin-2 and/or interferon)
Number of subjects: 782
Study: 12438678

Group type: EXPERIMENTAL
Intervention: Natural or synthetic surfactant
Number of subjects: 50
Study: 11019951

Group type: EXPERIMENTAL
Intervention: Frameless IUD
Number of subjects: 200

Group type: COMPARATOR
Intervention: TCu380A
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Frameless IUD and TCu380A
Number of subjects: 200
Study: 7547781

Group type: EXPERIMENTAL
Intervention: Argon laser drainage (ALD)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Suture needle drainage (SND)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 93
Study: 2185340

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus standard therapy followed by maintenance cisplatin for 6 months
Number of subjects: 462

Group type: COMPARATOR
Intervention: Standard surgery and radiation
Number of subjects: 462

Group type: COMPARATOR
Intervention: Induction chemotherapy (cisplatin and bleomycin) plus standard therapy
Number of subjects: 462
Study: 7000121

Group type: EXPERIMENTAL
Intervention: Preirradiation with 25 Gy of 42 MeV X‐rays
Number of subjects: 14

Group type: COMPARATOR
Intervention: No pretreatment (unirradiated)
Number of subjects: 14
Study: 30561061

Group type: EXPERIMENTAL
Intervention: Increased perceived stress
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Externalization coping and self-efficacy
Number of subjects: 90
Study: 28333533

Group type: EXPERIMENTAL
Intervention: BCT + IBT
Number of subjects: 61

Group type: COMPARATOR
Intervention: IBT
Number of subjects: 61
Study: 25375276

Group type: EXPERIMENTAL
Intervention: Promotora-delivered intervention with 11 home visits and 4 telephone calls, including a 12-minute episode of a situation comedy and a family workbook.
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Promotora-delivered intervention
Number of subjects: 361
Study: 23565578

Group type: EXPERIMENTAL
Intervention: High-flex posterior-stabilized (PS) TKA
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard cruciate-retaining (CR) TKA
Number of subjects: 36
Study: 21034839

Group type: EXPERIMENTAL
Intervention: 20 mL of normal saline injected into the knee joint cavity under ultrasonographic guidance
Number of subjects: 40

Group type: COMPARATOR
Intervention: No joint infusion (control group)
Number of subjects: 40
Study: 19384186

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcineurin inhibitor (CNI)
Number of subjects: 0
Study: 17287897

Group type: EXPERIMENTAL
Intervention: Famotidine, 20 mg/day
Number of subjects: 112

Group type: COMPARATOR
Intervention: Rebamipide, 300 mg/day
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 112
Study: 12812865

Group type: EXPERIMENTAL
Intervention: IPV subjects
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-abused controls
Number of subjects: 22
Study: 10767563

Group type: EXPERIMENTAL
Intervention: Formulation A - sodium chloride (0.9%) at pH 7.2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formulation B - sodium chloride (0.9%) at pH 5.8
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formulation C - Sorensens phosphate buffer (0.06 M) at pH 5.8
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formulation D - Sorensens phosphate buffer (0.13 M) at pH 5.8
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formulation E - Sorensens phosphate buffer (0.06 M) adjusted to pH 5.0
Number of subjects: 12

Group type: COMPARATOR
Intervention: All formulations (A to E)
Number of subjects: 12
Study: 8815751

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pravastatin + Nicotinic Acid (1.5 g)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pravastatin + Nicotinic Acid (2.25 to 3 g)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Combination therapy (Pravastatin + Nicotinic Acid)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 91
Study: 1319876

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Temafloxacin 600mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3938085

Group type: EXPERIMENTAL
Intervention: Spirohydantoin Sorbinil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aldose reductase inhibitors
Number of subjects: 0
Study: 31164290

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 83
Study: 29440045

Group type: EXPERIMENTAL
Intervention: Acupuncture plus rescue medication (RM)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Sham acupuncture plus RM
Number of subjects: 414

Group type: COMPARATOR
Intervention: Rescue medication (RM) alone
Number of subjects: 414
Study: 27449367

Group type: EXPERIMENTAL
Intervention: Triadic parent‐infant Relationship Therapy (TRT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (preterm infants)
Number of subjects: 65
Study: 25433184

Group type: EXPERIMENTAL
Intervention: SCCT-based educational intervention combined with EBP CPE program (standard-plus group)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: EBP CPE program alone (standard group)
Number of subjects: 580

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 580
Study: 21946819

Group type: EXPERIMENTAL
Intervention: Right ventricular outflow tract (RVOT) pacing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Right ventricular apical (RVA) pacing
Number of subjects: 60
Study: 21142385

Group type: EXPERIMENTAL
Intervention: Conservative treatment (antibiotics and percutaneous drainage if necessary, with or without interval appendectomy)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Urgent appendectomy (control group)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Conservative treatment (study group)
Number of subjects: 15
Study: 18328195

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1 percent cream plus clindamycin 1 percent gel
Number of subjects: 150

Group type: COMPARATOR
Intervention: Tretinoin 0.025 percent gel plus clindamycin 1 percent gel
Number of subjects: 150
Study: 15809121

Group type: EXPERIMENTAL
Intervention: Epidural S(+)‐ketamine 0.1 mg/kg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 0.5 microg/kg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Epidural S(+)‐ketamine 0.1 mg/kg plus epidural clonidine 0.5 microg/kg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (epidural saline)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 56
Study: 11903080

Group type: EXPERIMENTAL
Intervention: Combined femoral and sciatic nerve block with obturator nerve block (5 ml 0.75% ropivacaine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combined femoral and sciatic nerve block (15 ml 0.75% ropivacaine to each nerve)
Number of subjects: 60
Study: 9882786

Group type: EXPERIMENTAL
Intervention: Intraoperative autotransfusion (IAT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 7727178

Group type: EXPERIMENTAL
Intervention: Usual Care (UC)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All treatment groups pooled
Number of subjects: 72

Group type: COMPARATOR
Intervention: Dietary Intervention (D)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Diet plus cholestyramine (DC)
Number of subjects: 72
Study: 2186661

Group type: EXPERIMENTAL
Intervention: Gastric aspiration at the end of anaesthesia
Number of subjects: 201

Group type: COMPARATOR
Intervention: No gastric aspiration at the end of anaesthesia
Number of subjects: 201
Study: 371545

Group type: EXPERIMENTAL
Intervention: CP‐28,888‐27
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 31741126

Group type: EXPERIMENTAL
Intervention: Random forest model using conventional MRI sequences
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Random forest model using ADC images
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Combined model of T2WI FLAIR, post‐contrast T1WI, and ADC images
Number of subjects: 142
Study: 31638338

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 136

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 136
Study: 28454014

Group type: EXPERIMENTAL
Intervention: Mouse allergen-targeted integrated pest management (IPM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education
Number of subjects: 0
Study: 25754396

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 1 mg
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 25 mg
Number of subjects: 328

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study: 22540407

Group type: EXPERIMENTAL
Intervention: Aripiprazole (24 mg/day, reduced to 12 mg/day if needed for tolerability)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 258
Study: 23150126

Group type: EXPERIMENTAL
Intervention: Red pepper spice (1 g/d)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Turmeric (2.8 g/d)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 19486960

Group type: EXPERIMENTAL
Intervention: Interoceptive exposure
Number of subjects: 6

Group type: COMPARATOR
Intervention: Relaxation/distraction breathing-based technique
Number of subjects: 6
Study: 17690257

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study: 15519008

Group type: EXPERIMENTAL
Intervention: CrCl <60 ml/min
Number of subjects: 11187

Group type: EXPERIMENTAL
Intervention: CrCl 60 to 89 ml/min
Number of subjects: 11187

Group type: EXPERIMENTAL
Intervention: CrCl >89 ml/min
Number of subjects: 11187

Group type: COMPARATOR
Intervention: CrCl groups
Number of subjects: 11187

Group type: EXPERIMENTAL
Intervention: CKD patients undergoing follow-up angiography
Number of subjects: 11187
Study: 11225136

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 105

Group type: COMPARATOR
Intervention: Vitamin E capsules 400 units/day
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: T. arjuna tree bark powder 500 mg daily
Number of subjects: 105
Study: 9786807

Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 138

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138
Study: 7810184

Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of digoxin (0.8 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 11
Study: 2112083

Group type: EXPERIMENTAL
Intervention: Intravenous portal chemotherapy for 7 days
Number of subjects: 469

Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Transfused patients with chemotherapy
Number of subjects: 469

Group type: COMPARATOR
Intervention: Neither transfusions nor chemotherapy
Number of subjects: 469
Study: 333608

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (cephalosporin, 2 gm/day in divided doses for 5 days)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (cephalosporin)
Number of subjects: 77
Study: 31845139

Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 40 mg daily during the fasting period after ESD
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo during the fasting period after ESD
Number of subjects: 235
Study: 31182183

Group type: EXPERIMENTAL
Intervention: Intervention (lecture and group work on impulsivity, 1.5 hours)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Intervention group (female 5-HTTLPR s' allele carriers)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Intervention group (female DAT1 VNTR 10R/10R homozygotes)
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: DAT1 VNTR 9R carriers (particularly males)
Number of subjects: 1441
Study: 27837930

Group type: EXPERIMENTAL
Intervention: PneuX ETT
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard ETT
Number of subjects: 240